GSK PLC Sponsored ADR (NYSE:GSK) Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. grew its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 13.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,136,338 shares of the pharmaceutical company's stock after buying an additional 247,966 shares during the quarter. Envestnet Asset Management Inc. owned about 0.10% of GSK worth $82,762,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the business. Olde Wealth Management LLC purchased a new position in GSK in the 1st quarter valued at approximately $36,000. Lee Danner & Bass Inc. purchased a new position in GSK in the 4th quarter valued at approximately $39,000. Atala Financial Inc purchased a new position in GSK in the 4th quarter valued at approximately $45,000. First Pacific Financial purchased a new position in GSK in the 1st quarter valued at approximately $45,000. Finally, CX Institutional purchased a new position in GSK in the 1st quarter valued at approximately $46,000. 15.74% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Wall Street Zen downgraded GSK from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Hsbc Global Res raised GSK to a "strong sell" rating in a research report on Monday, April 28th. BNP Paribas began coverage on GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target for the company. Finally, Berenberg Bank reissued a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $37.38.

GSK Price Performance

GSK stock opened at $39.56 on Friday. GSK PLC Sponsored ADR has a 52-week low of $31.72 and a 52-week high of $44.67. The stock's fifty day simple moving average is $38.99 and its 200-day simple moving average is $37.23. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $80.98 billion, a price-to-earnings ratio of 20.39, a price-to-earnings-growth ratio of 1.57 and a beta of 0.50.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.82% and a net margin of 9.89%. The business had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. During the same quarter last year, the firm earned $0.43 earnings per share. The business's revenue was up 2.1% on a year-over-year basis. Equities research analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, July 10th. Investors of record on Friday, May 16th were issued a $0.4216 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a yield of 4.26%. This is a boost from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio (DPR) is presently 88.14%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.